{"filing":{"accession_number":"0001493152-26-025324","cik":"0001430306","ticker":"TNXP","company_name":"Tonix Pharmaceuticals Holding Corp.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226025324/form8-k.htm"},"events":[{"id":8825,"run_id":7747,"accession_number":"0001493152-26-025324","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Tonix Pharmaceuticals announced publication of a peer-reviewed Phase 1 clinical trial manuscript for TNX-1500 in the Journal of Clinical Immunology, demonstrating positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. This clinical development milestone is material to investors assessing the company's pipeline progress and de-risking of the lead drug candidate.","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2030,"accession_number":"0001493152-26-025324","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces publication of a peer-reviewed clinical trial manuscript for TNX-1500, a lead drug candidate, in the Journal of Clinical Immunology. For a biopharmaceutical company, positive Phase 1 clinical data publication is material to investors assessing pipeline progress and de-risking of the candidate. However, this does not fit neatly into the specific event taxonomy (not earnings, M\u0026A, litigation, impairment, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:26.727603+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2031,"accession_number":"0001493152-26-025324","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a Phase 1 clinical trial manuscript for TNX-1500 showing positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. While this is a clinical development milestone for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The positive Phase 1 data is material to investors assessing the company's pipeline prospects, making this a material event best classified as \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:26.727603+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2030,"accession_number":"0001493152-26-025324","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces publication of a peer-reviewed clinical trial manuscript for TNX-1500, a lead drug candidate, in the Journal of Clinical Immunology. For a biopharmaceutical company, positive Phase 1 clinical data publication is material to investors assessing pipeline progress and de-risking of the candidate. However, this does not fit neatly into the specific event taxonomy (not earnings, M\u0026A, litigation, impairment, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:26.727603+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-05-27"},{"id":2031,"accession_number":"0001493152-26-025324","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of a Phase 1 clinical trial manuscript for TNX-1500 showing positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. While this is a clinical development milestone for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation). The positive Phase 1 data is material to investors assessing the company's pipeline prospects, making this a material event best classified as \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:26.727603+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-05-27"}]}